Transforming Severe Asthma Care
Across the UK, innovative initiatives are enhancing asthma care and accelerating access to appropriate treatment
This website has been created and funded by AstraZeneca
Project 50 is an ambition shared by respiratory leaders and AstraZeneca, for 50,000 eligible patients with uncontrolled severe asthma to be accessing biologic treatment for severe asthma by 2028
We should be doing more to expand access to asthma biologics for those who need them, and the vision to reach 50,000 patients is a welcome move.
Dr. Hitasha Rupani
Consultant Respiratory Physician
Have you improved access to severe asthma biologics?
Submit your case study to be included in the Project 50 website, launching summer 2026, by clicking the button or emailing project50@astrazeneca.com.
Submit your case studySupport at every stage of your biologic journey
There will be specific resources available at every stage of severe asthma biologic adoption, to support your participation in Project 50.
Be the first to hear about the launch
Register for updates
Inside the platform: what to expect
- Pathway efficiency tool
- Case studies
- Pathway Accelerator programme
- Mentorship programme
- Resources toolkit
Explore resources
A tool to help identify patients with severe asthma*
*This is a Donated Service Programme funded by AstraZeneca & developed in collaboration with NHS England (NHSE) hosted Accelerated Access Collaborative (AAC)
To identify patients with suspected severe asthma or signs of poor asthma control on SABA therapy
This is a non-promotional medical resource funded by AstraZeneca.
Explore case studies with the project 50 Interactive map tool
This is a non-promotional medical resource funded by AstraZeneca.
GB-75152 | April 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
GB-75151 | April 2026
©2026 AstraZeneca. All rights reserved.
This website is intended for UK healthcare professionals only.
